Skip to content
value.today
Arcadia Biosciences, Inc. logo

Arcadia Biosciences, Inc.

Total raised
$37 M
3 rounds on record
Latest round
$19 M
Mar 2014
First round on record
Jul 2008
Today
Went public
See the company page

Arcadia Biosciences, Inc. is listed today as Arcadia Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Arcadia Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$4 MPrivate placement after listing$2 to $10 million

Arcadia Biosciences, Inc.: Private sale, Jun 2026

Investors in this round

5 investors had bought by the notice of Jun 26, 2026: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $11 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$395,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas J. Schaefer · Executive Officer, Director
  • Amy J. Yoder · Director
  • Gregory D Waller · Director
  • Kevin J. Comcowich · Director
  • Lilian Shackelford Murray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co, LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In addition to cash fee, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 271,845 shares of common stock at exercise price $1.2875 per share.”
  • On the amounts: “Includes gross proceeds received from issuance of pre-funded warrants & preferred investment options. Offering also reflects the aggregate exercise price of pre-funded warrants, preferred investment options and placement agent investment options issued.”

Signed by Thomas J. Schaefer, Ceo. Source: SEC Form D, newest notice filed Jun 26, 2026. Read the notice at the SEC.

equity, optionsSEC
Jan 2026$2 MPrivate placement after listing$2 to $10 million

Arcadia Biosciences, Inc.: Private sale, Jan 2026

Investors in this round

3 investors had bought by the notice of Jan 27, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$145,749
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas J. Schaefer · Executive Officer, Director
  • Albert D. Bolles · Director
  • Amy D. Yoder · Director
  • Deborah D. Carosella · Director
  • Gregory D. Waller · Director
  • Kevin J. Comcowich · Director
  • Lilian Shackelford Murray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co, LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In addition to the cash fee above, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 56,602 shares of common stock at an exercise price of $3.2188 per share”
  • On the amounts: “Includes gross proceeds received by company from issuance of shares upon exercise of warrants. Total offering also reflects the aggregate exercise price of inducement preferred investment options issued and placement agent investment options issued.”

Signed by Thomas J. Schaefer, Ceo. Source: SEC Form D, newest notice filed Jan 27, 2026. Read the notice at the SEC.

equity, optionsSEC
Jan 2021$25 MPrivate placement after listing$10 to $50 million

Arcadia Biosciences, Inc.: Private sale, Jan 2021

Investors in this round

26 investors had bought by the notice of Feb 16, 2021: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Common stock and warrants to purchase common stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,750,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew T Plavan · Executive Officer, Director
  • Pam T Haley · Executive Officer
  • Albert D Bolles · Director
  • Amy D Yoder · Director
  • Gregory D Waller · Director
  • Kevin T Comcowich · Director
  • Lilian Shackelford Murray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CT, NJ, NY

Signed by Pam Haley, Cfo. Source: SEC Form D, newest notice filed Feb 16, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2018$10 MPrivate placement after listing$10 to $50 million

Arcadia Biosciences, Inc.: Private sale, Mar 2018

Investors in this round

2 investors had bought by the notice of Apr 11, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Common stock and Warrants to Purchase Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$700,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew T Plavan · Executive Officer
  • Rajendra T Ketkar · Executive Officer, Director
  • Amy D Yoder · Director
  • Eric T Ray · Director
  • Gregory D Waller · Director
  • Kevin T Comcowich · Director
  • Uday T Garg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. LLC · New Hork, New YorkSold in NY

Signed by Matthew T Plavan, Cfo. Source: SEC Form D, newest notice filed Apr 11, 2018. Read the notice at the SEC.

equity, optionsSEC
Mar 2014$19 MNo. 3$10 to $50 million

Arcadia Biosciences, Inc.: Raise no. 3, Mar 2014

Investors in this round

8 investors had bought by the notice of Apr 25, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$19 M of $36 M offered; $17 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, other: Series D Preferred Stock and Warrants to Purchase Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Arizona

People named in the notice

  • Eric J. Rey · Executive Officer, Director
  • Darby J. Shupp · Director
  • James J. Reis · Director
  • Mark J. Wong · Director
  • Rachel J. Sheinbein · Director
  • Steven J. Brandwein · Director
  • Uday J. Garg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · Minneapolis, MinnesotaSold in AZ

Remarks in the notice

  • On fees: “Up to $2,000,000 will be paid to Piper Jaffray & Co. as sales compensation, assuming full subscription of Total Offering Amount”

Signed by Eric J. Rey, President and CEO. Source: SEC Form D, newest notice filed Apr 25, 2014. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$2 MNo. 2$2 to $10 million

Arcadia Biosciences, Inc.: Raise no. 2, Oct 2009

Investors in this round

6 investors had bought by the notice of Nov 25, 2009: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $12 M offered; $10 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$110,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Arizona

People named in the notice

  • Eric Rey · Executive Officer
  • Steven Brandwein · Executive Officer
  • David Collier · Director
  • James Reis · Director
  • Jonathan Thatcher · Director
  • Mark Wong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven F Brandwein, VP Finance and Administration. Source: SEC Form D, newest notice filed Nov 25, 2009. Read the notice at the SEC.

equitySEC
Jul 2008$15 MNo. 1$10 to $50 million

Arcadia Biosciences, Inc.: Raise no. 1, Jul 2008

Investors in this round

9 investors had bought by the notice of Aug 4, 2009: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$611,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Arizona

People named in the notice

  • Eric Rey · Executive Officer
  • Steve Brandwein · Executive Officer
  • David Collier · Director
  • James Reis · Director
  • Jonathan Thatcher · Director
  • Mark Wong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executives' payroll and benefits and board member remuneration”

Signed by Steve Brandwein, VP Finance & Administration. Source: SEC Form D, newest notice filed Aug 4, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Arcadia Biosciences, Inc., its revenue in fiscal 2024 came from these product and service lines: Royalty $30,000 (1%), License $10,000 (0%).

    Annual report (SEC XBRL) · Dec 2024

  • Arcadia Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jun 2026

Products and services#

No products or services of Arcadia Biosciences, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Arcadia Biosciences, Inc.
InvestorKindAmountRoundRoleSource
John G. Sperling 2012 Irrevocable Trust No. 1Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
John G. Sperling 2012 Irrevocable Trust No. 2Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
John G. Sperling 2012 Irrevocable Trust No. 3Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Mandala Agribusiness Co-Investments I LtdFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Mandala Agribusiness FundFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Moral Compass CorpCompanynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Vic C. KnaufPersonnot statednot statedHeld Series A and D preferred stock (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 9 investors.

Largest shareholders today

Institutions holding Arcadia Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arcadia Biosciences, Inc.
NameRoleNamed in
Thomas J. SchaeferExecutive officerJun 2026
Matthew T PlavanExecutive officerFeb 2021
Pam T HaleyExecutive officerFeb 2021
Rajendra T KetkarExecutive officerApr 2018
Eric J. ReyExecutive officerApr 2014
Eric ReyExecutive officerNov 2009
Steven BrandweinExecutive officerNov 2009
Steve BrandweinExecutive officerAug 2009
Amy J. YoderDirectorJun 2026
Gregory D WallerDirectorJun 2026
Kevin J. ComcowichDirectorJun 2026
Lilian Shackelford MurrayDirectorJun 2026
Thomas J. SchaeferDirectorJun 2026
Albert D. BollesDirectorJan 2026
Amy D. YoderDirectorJan 2026
Deborah D. CarosellaDirectorJan 2026
Gregory D. WallerDirectorJan 2026
Albert D BollesDirectorFeb 2021
Amy D YoderDirectorFeb 2021
Kevin T ComcowichDirectorFeb 2021
Matthew T PlavanDirectorFeb 2021
Eric T RayDirectorApr 2018
Rajendra T KetkarDirectorApr 2018
Uday T GargDirectorApr 2018
Darby J. ShuppDirectorApr 2014
Eric J. ReyDirectorApr 2014
James J. ReisDirectorApr 2014
Mark J. WongDirectorApr 2014
Rachel J. SheinbeinDirectorApr 2014
Steven J. BrandweinDirectorApr 2014
Uday J. GargDirectorApr 2014
David CollierDirectorNov 2009
James ReisDirectorNov 2009
Jonathan ThatcherDirectorNov 2009
Mark WongDirectorNov 2009

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.